UroGen Pharma(URGN) - 2023 Q4 - Earnings Call Transcript

Importantly, in patient interviews conducted during the ENVISION trial patients overwhelmingly prefer UGN102 and said they would recommend it to other patients, highlighting the lack of disruption to daily life and that UGN-102 was less invasive, less painful and less time consuming than the standard of care. Finally, as Liz mentioned at the beginning of the call, we are pushing ahead with next-generation formulations of our upper tract and bladder products for low-grade urothelial cancers. We look forward ...